Profoundly different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases

Citation

As Published
http://dx.doi.org/10.1073/pnas.1312006110

Publisher
National Academy of Sciences (U.S.)

Version
Final published version

Accessed
Wed Jan 23 09:58:31 EST 2019

Citable Link
http://hdl.handle.net/1721.1/89098

Terms of Use
Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.

Detailed Terms

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.
Profundely different prion diseases in knock-in mice carrying single PrP codon substitutions associated with human diseases

Walker S. Jackson\textsuperscript{a,b,c,1}, Andrew W. Borkowski\textsuperscript{a,b,c}, Nicki E. Watson\textsuperscript{a}, Oliver D. King\textsuperscript{a}, Henryk Faas\textsuperscript{a}, Alan Jasanoff\textsuperscript{a,f,1}, and Susan Lindquist\textsuperscript{a,b,c,2}

\textsuperscript{a}Whitehead Institute for Biomedical Research, Cambridge, MA 02142; \textsuperscript{b}Howard Hughes Medical Institute, \textsuperscript{c}Department of Biology, and \textsuperscript{d}Departments of Biological Engineering, Brain and Cognitive Sciences, and Nuclear Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; \textsuperscript{e}Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA 01655; and \textsuperscript{f}Frances Bitter Magnet Laboratory, Cambridge, MA 02139

Contributed by Susan Lindquist, July 9, 2013 (sent for review March 7, 2013)

In man, mutations in different regions of the prion protein (PrP) are associated with infectious neurodegenerative diseases that have remarkably different clinical signs and neuropathological lesions. To explore the roots of this phenomenon, we created a knock-in mouse model carrying the mutation associated with one of these diseases [Creutzfeldt-Jakob disease (CJD)] and exactly analogous to a previous knock-in model of a different prion disease (familial amyloidotic polyneuropathy (FAP)). Together with the WT parent, this created an allelic series of three lines, each expressing the same protein with a single amino acid difference, and with all native regulatory elements intact. The previously described FAP mice develop neuronal loss and intense reactive gliosis in the thalamus, as seen in humans with FAP. In contrast, CJD mice had the hallmark features of CJD, spongiosis and proteinase K-resistant PrP aggregates, initially developing in the hippocampus and cerebellum but absent from the thalamus. A molecular transmission barrier protected the mice from any infectious prion agents that might have been present in our mouse facility and allowed us to conclude that the diseases occurred spontaneously. Importantly, both models created agents that caused a transmissible neurodegenerative disease in WT mice. We conclude that single codon differences in a single gene in an otherwise normal genome can cause remarkably different neurodegenerative diseases and are sufficient to create distinct protein-based infectious elements.

Prion diseases are among the most enigmatic and fascinating subjects in biology from the standpoint of the diseases of protein folding. They involve highly unusual infectious agents (prions) that lack any detectable information-bearing nucleic acid and instead rely on the self-templated misfolding of an otherwise benign protein [i.e., prion protein (PrP)] to encode the disease (1). Prion diseases share several features with other neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson disease (PD). All typically affect people late in life, and all are characterized by the accumulation and aggregation of misfolded proteins (2, 3). Further, the misfolded proteins that precipitate in these diverse diseases are broadly expressed and are not more abundant in the brain areas that are most severely affected by disease. Intensifying interest in the prion diseases, recent evidence has established that the proteins involved in AD and PD (affecting a far larger patient population than the prion diseases) have self-templating properties that have traditionally been thought to be unique to the prion protein (3). The AD and PD proteins, Aβ and α-synuclein, do not produce infectious agents, but their self-templating properties profoundly influence their pathogenicity (4–6). An understanding of the underlying mechanisms is urgently needed. The PrP, with its highly distinct pathologies and pathological progressions that are linked to it, provides an important general model for such investigations.

There are several types of human prion diseases, each beginning with pathologic processes in a different brain region and leading to distinct functional deficits: cognition [Creutzfeldt-Jakob disease (CJD)], movement control (Gerstmann-Sträussler-Scheinker syndrome), or sleep and autonomic functions (fatal familial insomnia (FFI)) (7). Prion diseases also affect animals and include bovine spongiform encephalopathy (BSE) of cattle, scrapie of sheep and goats, and chronic wasting disease (CWD) of deer and elk (1). Importantly, all forms of prion diseases appear to be caused by misfolded PrP.

Historically, prion diseases were studied by injecting infectious material into indicator mice to model prion diseases initiated by the transmission of an exogenous agent (i.e., acquired disease). However, like other more conventional neurodegenerative diseases, most cases of prion diseases in humans are caused by the inheritance of mutations or occur sporadically (i.e., with uncertain causes) (8). Here, our goal was to model genetic forms because different mutations are linked to different diseases.

More than 20 mutations in the prion protein gene (PRNP) are associated with human prion diseases, many with specific pathological changes and clinical signs (7). Despite decades of research, it remains unclear why different mutations lead to different diseases. Because the mutations arise in different people, one possibility is that host-specific factors might cause these different phenotypes. Another is that the mutations simply sensitize carriers to infection by distinct prion variants encountered in the environment. The countervailing hypothesis is that different PRNP mutations induce specific misfolding events that occur in different specific regions of the brain or that occur broadly but affect only specific regions. Difficulties in generating mouse models that develop disease spontaneously have impeded our understanding. The use of randomly integrated transgenes to model familial forms of prion disease in mice has the widely sought advantage of producing higher-than-normal expression levels, which enhance the rate of misfolding and accelerate disease. However, the resulting mice are prone to variable, and typically incorrect, spatial expression patterns. Indeed, this may explain why most mouse models that have been engineered this way are disease-free. Moreover, because mice with very high overexpression of WT PrP can develop diseases (9–11), in transgenic models, it is difficult to distinguish between the effects of the mutation from the effects of overexpression.

The authors declare no conflict of interest.

Present address: German Center for Neurodegenerative Diseases, 53127 Bonn, Germany.

To whom correspondence should be addressed. E-mail: lindquist_admin@wi.mit.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1312006110/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1312006110

PNAS Early Edition | 1 of 6
The alternative knock-in approach has been used much less commonly because of the greater degree of difficulty involved. Moreover, within the limited lifetime of a mouse, most knock-in models of late-onset neurodegenerative disorders do not develop spontaneous disease. (Notable exceptions include polyglutamine disease models that carry expansion mutations severe enough to cause disease in younger humans, or models that use ectopic loci or nonnative promoters.) In earlier work, only one knock-in line had been generated for a familial PRNP mutation associated with human disease, P101L (12). (Throughout the present report, we use mouse Pmp codon numbering, which is −1 compared with human PRNP as a result of a single amino acid deletion in the N terminus.) This mouse was disease-free and pathology-free, and did not produce infectious material (12). We hypothesized that the P101L mutation might not be a poor candidate to cause disease in the short lifespan of the mouse because it is associated with a very slowly progressing neurodegenerative disease in humans. Further, the P101L substitution is located in a region of the protein that is already unstructured and would be expected to have a relatively modest influence on the protein’s stability (13). Therefore, we developed a knock-in mouse strain that carried a mutation in the structured region of the protein, more likely to cause misfolding, and associated with rapidly progressing disease in humans (14).

Two knock-in mouse lines were analyzed, one a control without a disease mutation and one carrying the aspartate-to-asparagine substitution associated with FFI, D177N (14). Both mice carried a 2-aa substitution (L108M, V111M) known as the 3F4 epitope, which served several purposes. First, this epitope is encoded by the human gene, making our constructs closer to the human version. Second, this epitope creates a transmission barrier (confirmed in our report; ref. 14) that reduces the possibility of mice becoming infected by exogenous mouse prions. Third, it creates a convenient antigenic tool for distinguishing the protein generated by the knock-in gene from the allelic WT protein in WT brains, indicating the CJD mutation did not occur within the short lifespan of a mouse. Because humans homozygous for the CJD mutation develop disease faster than heterozygotes (16), we focused on homozygous mice.

The PrP protein in the brains of our CJD mice was expressed to cause disease in younger humans, or models that use ectopic loci or nonnative promoters.) In earlier work, only one knock-in line had been generated for a familial PRNP mutation associated with human disease, P101L (12). (Throughout the present report, we use mouse Pmp codon numbering, which is −1 compared with human PRNP as a result of a single amino acid deletion in the N terminus.) This mouse was disease-free and pathology-free, and did not produce infectious material (12). We hypothesized that the P101L mutation might not be a poor candidate to cause disease in the short lifespan of the mouse because it is associated with a very slowly progressing neurodegenerative disease in humans. Further, the P101L substitution is located in a region of the protein that is already unstructured and would be expected to have a relatively modest influence on the protein’s stability (13). Therefore, we developed a knock-in mouse strain that carried a mutation in the structured region of the protein, more likely to cause misfolding, and associated with rapidly progressing disease in humans (14).

Figure 1. Clinical abnormalities of CJD mice. (A) Median time (±SEM) mice remained on the rotarod during each trial. Red triangles, green diamonds, and blue dots represent WT, CJD, and FFI data, respectively. Color-coded asterisks are placed above the triangles where WT mice had better scores (*P < 0.05) than CJD (green) or FFI (blue) mice, calculated with the non-parametric Mann-Whitney test. Numbers of mice: WT, n = 14; CJD, n = 11; FFI, n = 19. (B) The median (±SEM) amount of burrowing matrix remaining in the burrowing chambers. Compared with WT mice (red), CJD mice (green) removed less (*P < 0.05, nonparametric Mann-Whitney test) but FFI mice (blue) did not. Numbers of mice: WT, n = 14; CJD, n = 9; FFI, n = 9. (C) Phenotypic array representing median differences between WT and CJD mice for specific behaviors, labeled (Right). Yellow tiles depict comparisons for which the CJD mice scored higher than WT; cyan represents the opposite. The brightness corresponds to the magnitude of the difference. The age in months is directly below the array. The number of animals for each comparison is immediately above the array. (D) Scatter plot of the data making up the tile “turn” at 16 mo (framed in white). Error bars depict mean and quartile values.

Results

Generation of CJD Knock-In Mice. We used our previous strategy (14) to develop a CJD knock-in line that differs from the WT line by a single glutamate-to-lysine codon substitution (Fig. S1). A major challenge in developing mouse models of neurodegenerative disease is to accelerate disease processes, which typically require at least four decades to develop in humans, so that they
Clinical Abnormalities in CJD Mice. The behaviors of the mice were compared in diverse assays. The rotarod is an instrument that tests their ability to walk on a cylinder rotating at an accelerating pace. Experiments were performed on 18-mo-old mice, three times each day for three consecutive days. Upon the first trial, all mice performed poorly, with median times of less than 5 s (Fig. L4, trials 1–3). Median rotarod times improved for all lines with repeated trials, but CJD mice lagged far behind WT mice at later time points. FFI mice performed only slightly worse than WT mice (Fig. L4, trials 7–9).

Another assay exploited the strong, instinctive drive of mice to build burrows (17) (Movie S1). We tested their ability to remove a burrowing matrix from a tube placed in a large cage, a task that is performed quickly and efficiently by healthy mice. CJD mice were only half as efficient as WT mice ($P < 0.05$, Mann–Whitney test; Fig. 1B). The slightly reduced performance of FFI mice was not statistically significant (Fig. 1B).

Finally, we used automated mouse behavioral analysis (AMBA), a computerized system that quantifies the activities of mice in their home cages (18). The key benefits of AMBA are that animals are allowed to roam freely in the absence of interventions by experimenters, with 24 spontaneous activities scored by computer in an unbiased manner (Movie S2). This system enables the detection of behavioral changes before overt neurological abnormalities. More than 1 billion video frames were analyzed in these experiments. A composite of the data are presented in a highly condensed, readily comparable form—as a “phenotypic array”—in Fig. 1C. Representative data corresponding to several individual behaviors over a 24-h period for each mouse tested are shown in Fig. 1D and Fig. S2.

CJD mice had normal amounts of “rest,” a correlate of sleep (Fig. 1C and Fig. S2). In contrast, FFI mice had abnormally high rest (14). “Turn,” a metric frequently scored during body twisting, was very strongly reduced in CJD mice (Fig. 1C and D and Fig. S2), but this behavior was rarely abnormal in FFI mice (14). “Cuddled hang,” measured as hanging from the ceiling of the cage, was strongly reduced in both mutant lines but more so in CJD mice (Fig. 1C and Fig. S2). CJD mice in general spent less time doing physically demanding behaviors (“jump,” “rear,” and “cuddled hang”) and more time with resting-related behaviors (“twitch during rest” and “awaken”; Fig. 1C and Fig. S2). The more quiescent behaviors of CJD mice overall represented a general reduction in activity rather than the specific disturbance in sleep we observed in FFI mice (14).

Distinct Histopathological Changes in CJD Mice. To reveal neuropathological changes, we used a variety of histological techniques. We first examined paraffin-embedded 4-μm-thick sections stained with H&E. CJD mice had prominent spongiform degeneration in the hippocampal CA1 region (Fig. 2A), specifically in the synapse-rich area (i.e., neuropil) of the molecular layer. FFI brains did not (Fig. 2B). In humans, spongiosis is a rare feature that distinguishes most of the prion diseases, including CJD but not FFI, from other neurodegenerative diseases (19). Other notable differences between the mice also characteristically distinguish CJD and FFI diseases in humans. For example, FFI brains had dilated ventricles, atrophied cerebella, and massive neuronal loss in the thalamus (14), but CJD brains did not.

A hallmark of most neurodegenerative diseases is an increase in the size and/or number of astrocytes, a pathological state known as reactive gliosis. This was present in CJD hippocampi and deep cerebellar white matter (Fig. S3), but was notably absent from the thalamus. In contrast, FFI brains had severe reactive gliosis in the thalamus, and in the deep cerebellar white matter, but not in the hippocampus (14).
Next, ultrathin sections were examined by EM. Surprisingly, the PrP\textsuperscript{res} aggregates in CJD brains that were observed by light microscopy were not detected by EM. Although it seems counterintuitive, this distinction has been reported by others (19).

In sharp contrast, PrP\textsuperscript{res} aggregates were not detected in FFI brains by using standard procedures. We did, however, find numerous fibrillar deposits in FFI brains by EM, specifically in the thalamus (Fig. S5). [This region of the brain is particularly affected by FFI pathologic processes, although it was negative for many amyloid stains (14).] Standard epitope retrieval procedures are too harsh to be useful for EM. However, mild fixation permitted modest labeling of these deposits with PrP antibodies (Fig. S5). Similar deposits were never observed in CJD mice, which we found perplexing (SI Discussion). The requirement for two very different methods to detect PrP aggregates in these two disease models indicates that the mutations, carried by the same protein and expressed from the same genomic locus, created different types of misfolding. These observations complement aforementioned differences in stability and glycosylation, confirming that the two mutant forms of PrP populate distinct conformational states in the mouse brain.

Additional Changes in CJD Brains. To identify additional differences between our mutant mice we used some additional imaging technologies. First, we used an activity-dependent MRI technique that detected, in living mice, changes in brain regions that appeared normal with conventional histological methods (23).

This approach revealed structural changes in the cerebellum and ventricles and a reduced MRI signal (likely a result of reduced neuronal activity) in the thalamus of FFI mice (14). In contrast to FFI brains, MRI did not reveal any gross structural changes in the CJD brains (Fig. S6).

To determine if additional regions were degenerating, we examined markers of early stages of programmed cell death (PCD). In this highly conserved biological process, cells deliberately activate signaling cascades, which, when past a series of checkpoints, cause them to die. Endonuclease G (EndoG) is a mitochondrial protein that increases in total levels during disease and translocates to a perinuclear location, and eventually to the nucleus, to facilitate PCD (24). As expected, it was absent from WT brains. Surprisingly, given the normal results from other tests for pathologic conditions, EndoG was present specifically in the thalami of CJD brains, although less intense than in FFI brains (Fig. 3 A–C). Another PCD protein is apoptosis inducing factor, which migrates from mitochondria to the cytosol, and eventually into the nucleus to trigger cell death (25). Although WT brains were negative, perinuclear deposits were detected in the thalami of FFI mice (Fig. S7), and, surprisingly, only in the thalami of CJD mice as well (Fig. S7). Thus, despite appearing normal with other tests of pathology, the CJD thalamus contained signs of PCD, whereas the hippocampus and cerebellum did not (SI Discussion).

Most neurons in adult mammalian brains are postmitotic, but, during neurodegenerative disease, a small number of neurons reexpress cell cycle markers (26). We therefore probed brain sections for changes in several cell cycle-related proteins. Although most proteins we examined were not abnormally expressed (Methods), two were. Proliferating cell nuclear antigen (PCNA), a protein associated with mitotically active cells, is found in neuronal nuclei of neurodegenerative diseased brains (27, 28). It was intensely present in small, glial-sized nuclei of all brain sections, as expected. PCNA was also found in neuronal nuclei in the FFI thalamus, but not the CJD thalamus (Fig. S7). Interestingly, in CJD and FFI brains, neuronal nuclei in the superior colliculus were PCNA-positive (Fig. S7).

H2A.X is a histone protein that becomes phosphorylated in response to dsDNA breaks that occur during normal cell division. Adult neurons are nondividing, and H2A.X is associated with the degenerative process (27, 28). Tiny punctate nuclear deposits were present throughout WT brains (Fig. 3D). Abnormally large nuclear puncta were also present in striatal neurons of CJD but not FFI brains (Fig. 3 E and F).

Disease in CJD Mice Is Transmissible. Because human E200K carriers can live into the ninth decade of life before disease onset (7), we were not surprised that many CJD mice lived as long as 2 y without being terminally ill, but some did not. To determine if CJD mice developed spontaneous prion infectivity, brain homogenates from mice that were terminally ill at 14 or 21 mo of age were injected intracranially into several strains of indicator mice. They were examined weekly by an individual highly experienced with detecting neurological illness in mice but blinded to the design of the experiments. Importantly, when injected with brain homogenates from aged WT mice, none of the indicator mice developed behavioral or neuropathological abnormalities (14, 29). KO mice that do not express PrP were challenged with CJD homogenates and remained healthy (Fig. 4A), which was expected because expression of PrP is required for susceptibility to prion infectivity (30).

Our test for infectivity first used an indicator mouse strain (known as Tga20) that overexpresses PrP and is especially sensitive to prion infection (14, 29). At 1 y after injection with CJD homogenates, Tga20 mice became terminally ill with reduced body condition (observed as abnormally loose skin), kyphosis, and a highly unusual gait (Fig. 4A and Movie S3). In contrast, Tga20 mice injected with FFI homogenates developed ataxia, a highly unusual paroxysmal hind limb twitch (14), and, later, a persistent scratching activity (i.e., pruritus). CJD inocula induced spongiosis in many areas, including the thalamus (Fig. 4B), and punctate PrP\textsuperscript{res} deposits particularly in the cerebellum (Fig. 4C). In contrast, FFI inocula induced neuronal loss and reactive gliosis in the thalamus and a striking dilation of the lateral ventricles, but not spongiosis or PrP\textsuperscript{res} (14).

Two gold standards of infectious prion diseases are the serial transmission of the infectious agent and its resistance to physical treatments that kill conventional microorganisms, such as high temperatures. Brain homogenate from a Tga20 mouse that had died of the aforementioned CJD infection was split into four aliquots and incubated at 0, 50, 70, or 90 °C for 30 min. Each aliquot was then injected into four to six Tga20 mice. Importantly,
all four aliquots induced disease with similar incubation periods of 50 to 60 wk (Fig. 4C). Histopathologic analysis revealed that their brains developed the spongiosis and coarse PrP<sup>res</sup> aggregates characteristic of infectious CJD in humans (Fig. 4D).

Mice that express WT PrP at endogenous levels provide an even more rigorous indicator of infectious prions. Although they are slower to develop acquired disease, they never develop any PrP-related pathologic conditions, even late in life. We took this principle a step further by using our knock-in WT mice carrying the 3F4 epitope, which makes them resistant to infection by prion infectivity. Because prion diseases are infamous for their ability to spread between individuals, they are assumed to easily spread within an individual brain. Thus, it was surprising that the thalamus was primarily affected in FFI mice and the hippocampus was primarily affected in CJD mice, as these regions are adjacent. It was also surprising that, in CJD brains, spongiosis and PrP<sup>res</sup> intensity increased as the disease progressed, but there was little spreading into neighboring areas. Although they are not likely to be naturally transmissible (3, 37), several other neurodegenerative diseases can be induced by intracerebral injection of diseased brain (4, 6, 38), and some have features reminiscent of prion strains and transmission barriers (5). This has led to renewed interests in spreading mechanisms for many neurodegenerative diseases, whereby a pathologic state is initiated in one area and then spreads to others in a prion-like fashion (2, 39).

Because prion diseases are infamous for their ability to spread between individuals, they are assumed to easily spread within an individual brain. Therefore, although the CJD and FFI mutations appear to modify PrP’s structure differently, they are both sufficient to induce the spontaneous production of prion infectivity.

**Discussion**

We have created a knock-in mouse model of a familial prion disease, CJD, that causes a late-onset neurodegenerative disease and also generates a spontaneous infectious prion agent. Mouse models rarely recapitulate human disease pathologic conditions without gross overexpression of the disease-associated protein. However, the CJD knock-in mice we created here, by simply changing a single amino acid in the endogenous ORF, develop many hallmarks of the human diseases to which they correspond. Their disease phenotypes, and the nature of the infectious agents they produce, are very different from those of the FFI mice we created earlier (summary in Fig. S8), which instead develop several neurodegenerative characteristics of human FFI. Notably, consistent with in vitro biophysical studies by others (13), the two mutant PrP proteins had different stabilities in the brain. Given that the mice were created by knock-in manipulations in the same ES cell line, and were crossed to the same genetic background, their distinct disease phenotypes can be attributed to the distinct physical properties of the single amino acid substitutions they carry.

Integration of the two transgenic lines carrying the same E199K CJD mutation not develop disease or infectivity (31, 32). One possibility is that our mice expressed a mouse/human PrP chimera, whereas the other mice expressed the mutation in the context of mouse or human PrP (31, 32). In our experiments, the WT version of this mouse/human chimera had a stability and trafficking pattern in mouse brain that was indistinguishable from that of the endogenous mouse protein. However, in the course of the 12 mo required to establish disease, a subtle difference in the stability of the chimeric protein could contribute to the phenotypic distinctions resulting from the additional causing mutations. Another possibility is that knock-in mutations are required to produce spontaneous infectivity because they uniquely recapi-tulate the complex regulation to which the endogenous PrP gene is subject. Randomly integrated transgenes have the advantage of being far less labor-intensive to engineer. However, they are prone to variable expression levels and patterns, depending on copy number and genome integration site. Indeed, one of the most popular vectors for modeling neurodegenerative diseases, a Prnp promoter fragment lacking an intron that contains regulatory information, is highly prone to integration effects (23, 33, 34).

Even very large vectors such as those created by BACs can have variable spatial expression patterns (35). This likely explains why some lines overexpressing WT PrP become sick (9–11). It also highlights why, in the rare past cases in which spontaneous infectivity has been generated by extremely high overexpression levels in transgenic mice, it has been difficult to determine how much the mutation contributed to the result (36).

Because prion diseases are infamous for their ability to spread between individuals, they are assumed to easily spread within an individual brain. Therefore, although the CJD and FFI mutations appear to modify PrP’s structure differently, they are both sufficient to induce the spontaneous production of prion infectivity.
However, our work establishes that this mutation can cause disease spontaneously. More broadly, our work has implications for the origin of the BSE epidemic during the 1980s, which caused the “new variant” CJD crisis in humans in the 1990s (40). It is commonly assumed that this epidemic was initiated by an animal that acquired prion disease from the consumption of scrapie-infected sheep brains (41). Our work supports an alternative explanation: that the process started in a cow carrying a PrP mutation that spontaneously gave rise to infectious material and was then spread by the inclusion of cow brain in protein-rich feed (40). Similarly, it has been assumed that CWD, a rapidly spreading prion disease of free-roaming deer, moose, and elk in North America (42), was initiated by the accidental exposure of wildlife to a contaminated environment. However, it may well have arisen directly and spontaneously in deer as a result of a mutation in PrP, especially in light of the spontaneous development of a severe infectious prion disease in transgenic mice expressing a CWD-related epitope (29). In any case, PrP is unusually vulnerable to misfolding events that generate conformations with a toxic gain of function: the protein is rather small (only 254 aa) yet more than 20 different PrP mutations cause neurodegenerative disease in humans. Our work establishes that spontaneous mutations in the endogenous PrP gene can readily produce not only disease, but also infectious agents.

Methods

Most methods were described previously (14, 18, 23). Animal experimentation protocols were approved by the Committee on Animal Care, Massachusetts Institute of Technology. Details of Western blots, antibodies used, measurements of disease, and EM are provided in SI Methods.

ACKNOWLEDGMENTS. The authors thank M. Duquette and A. Topolszki for excellent technical assistance and J. Ma, A. Steele, and several other laboratory members for critical evaluation of this manuscript. This work was funded by a National Institutes of Health National Research Service Award Fellowship (to W.S.J.) and US Department of Defense funding (A.J. and S.L.).